Drug Development in Psychiatry / edited by Matthew Macaluso, Sheldon H. Preskorn, Richard C. Shelton.

Format:

Book

Contributor:

Macaluso, Matthew, editor.

Preskorn, Sheldon H., editor.

Shelton, Richard C., editor.

Series:

Advances in Neurobiology, 2190-5223 ; 30

Language:

English

Subjects (All):

Neurochemistry.

Pharmacology.

Psychiatry.

Local Subjects:

Neurochemistry.

Pharmacology.

Psychiatry.

Physical Description:

1 online resource (457 pages)

Edition:

1st ed. 2023.

Place of Publication:

Cham : Springer International Publishing : Imprint: Springer, 2023.

Summary:

This new book reviews clinical trial methodology as it pertains to drug development in psychiatry. The authors will describe the process of drug development in psychiatry from discovery through marketing with the help of clinically relevant examples. The history of drug development in psychiatry is explored dating back to the era of serendipitous discovery and culminating in an era of new and highly focused targets. The book will delineate how drug development in psychiatry has changed and adapted with the discovery of drugs with novel mechanisms of action. Drug Development in Psychiatry elucidates how biomarkers, genetics, and advances in neuroscience and neuroimaging have influenced drug development approaches, which will ultimately change the practice of psychiatry. The book charts the early years of drug discovery by chance observation, reviews the developments of the past 50 years of refined targeting of CNS drugs without the discovery of mechanistically new drugs, and looks to the discovery of mechanistically new drugs, the examination of new targets, genetics, and biomarkers.

Contents:

Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development

The History of Drug Development in Psychiatry: A Lesson in Serendipity

The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric Disorders

Discovery and Development of Monoamine Transporter Ligands

Drug Development for New Psychiatric Drug Therapies

Post-Approval Research in Drug Development: Priorities and Practices

Discovery of new transmitter systems and hence new drug targets

Reverse engineering drugs

Back to the Future of Neuropsychopharmacology

Targeted Treatments for Fragile X Syndrome

The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders Diseases

Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics

The role of fMRI in drug development: an update

Monoamine Oxidase B (MAO-B): A Target for Rational Drug Development in Schizophrenia Using PET Imaging as an Example

Genomics in Treatment Development

Increased Inflammation and Treatment of Depression: from Resistance to Reuse, Repurposing and Redesign

Experimental medicine approaches in early phase CNS drug development.

Notes:

Includes bibliographical references and index.

Other Format:

Print version: Macaluso, Matthew Drug Development in Psychiatry

ISBN:

3-031-21054-9